Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/05/06 21:34:35」(JST)
wiki en
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. von Willebrand病の臨床症状および診断 clinical presentation and diagnosis of von willebrand disease
- 2. 血小板機能検査 platelet function testing
- 3. 後天性フォン・ヴィレブランド症候群 acquired von willebrand syndrome
- 4. 出血性素因を有する成人患者へのアプローチ approach to the adult patient with a bleeding diathesis
- 5. von Willebrand因子の生物学および正常機能 biology and normal function of von willebrand factor
English Journal
- Role of zebrafish thrombocyte and non-thrombocyte microparticles in hemostasis.
- Kim S, Carrillo M, Radhakrishnan UP, Jagadeeswaran P.AbstractHemostasis is a defense mechanism that protects an organism from bleeding in the event of injury. We have previously demonstrated the utility of the zebrafish as a model to study human hemostasis. However, there are no studies on the role of microparticles in hemostasis in early vertebrates. Studying microparticles in zebrafish may provide insight into the evolution of microparticle function in hemostasis and may lead to direct observation of these microparticles in zebrafish larvae due to transparency of the vessels. In this investigation we demonstrate the presence of cellular microparticles in fish blood by both immunostaining as well as by using zebrafish whose thrombocytes are labeled with green fluorescent protein. Further investigation showed that microparticles were also labeled by fluorescein isothiocyanate annexin V, suggesting that these particles are derived via apoptosis. A portion of the fluorescein isothiocyanate annexin V labeled microparticles was also labeled by DiI-C(18). Labeling by DiI-C(18) suggests that some microparticles are derived from young thrombocytes. Additionally, GpIIb antibody labels almost all thrombocyte-derived microparticles and a greater percentage of microparticles are labeled by GpIIb antibody than by DiI-C(18). This suggests that thrombocyte microparticles are derived from both young and mature thrombocytes. Furthermore, the increase of microparticles by adding excessive microparticles into blood in vitro and through intravenous injections led to an increased hemostatic response. In addition, treatment with tumor necrosis factor alpha resulted in an increased number of thrombocyte microparticles and enhanced hemostasis; in contrast, treatment with zVAD-FMK, a caspase inhibitor, resulted in a decrease in thrombocyte microparticles and decreased hemostasis. We also found that thrombocyte microparticles agglutinate, along with other cells and cellular microparticles, in the presence of an excess of either ristocetin or ultra-large von Willebrand factor. Also, stimulation of von Willebrand factor release in vivo resulted in clusters of thrombocyte microparticles in the veins. Moreover, thrombocyte microparticles were the first to appear at the site of arterial injury. We found that thrombocyte microparticles are functionally equivalent to platelet microparticles. The microparticles initiate arterial thrombus formation in a von Willebrand factor-dependent manner and further enhance thrombus formation by forming clusters of microparticles in venous thrombosis. This finding may have applications for understanding the role of platelet microparticles in humans and may have diagnostic applications.
- Blood cells, molecules & diseases.Blood Cells Mol Dis.2012 Mar 15;48(3):188-96. Epub 2012 Feb 3.
- Hemostasis is a defense mechanism that protects an organism from bleeding in the event of injury. We have previously demonstrated the utility of the zebrafish as a model to study human hemostasis. However, there are no studies on the role of microparticles in hemostasis in early vertebrates. Studyin
- PMID 22306208
- A Carrier Protein Strategy Yields the Structure of Dalbavancin.
- Economou NJ, Nahoum V, Weeks SD, Grasty KC, Zentner IJ, Townsend TM, Bhuiya MW, Cocklin S, Loll PJ.SourceDepartment of Biochemistry and Molecular Biology, Drexel University College of Medicine , Philadelphia, Pennsylvania 19102, United States.
- Journal of the American Chemical Society.J Am Chem Soc.2012 Mar 1. [Epub ahead of print]
- Many large natural product antibiotics act by specifically binding and sequestering target molecules found on bacterial cells. We have developed a new strategy to expedite the structural analysis of such antibiotic-target complexes, in which we covalently link the target molecules to carrier protein
- PMID 22352468
Japanese Journal
- von Willebrand因子とvon Willebrand病
- 松下 正
- 現代医学 58(2), 239-251, 2010-12
- NAID 40018779804
- von Willebrand因子(抗原および活性),von Willebrand因子multimer構造,von Willebrand因子リストセチンコファクター (広範囲 血液・尿化学検査 免疫学的検査(第7版・2)その数値をどう読むか) -- (血液凝固・線溶系検査)
- 後藤 信哉
- 日本臨床 68(-), 707-711, 2010-01
- NAID 40016932936
Related Pictures
★リンクテーブル★
| リンク元 | 「リストセチン」 |
| 拡張検索 | 「ristocetin co factor activity in von Willebrand factor」 |
「リストセチン」
- 英
- ristocetin
- 関
- 血小板凝集能
- 放線菌が産生する抗生物質
- グリコペプチド系抗生物質。米国で使用されていたが，現在では販売中止。
- 人の血小板を凝集させる作用がある。GpIb/GpIXとvWFとの相互作用を促進し、血小板を凝集させるらしい。
- リストセチン凝集はvWFの機能に規定されるので、von Willebrand病の診断に用いられる。
「ristocetin co factor activity in von Willebrand factor」
- 関
- also von Will ebrand factor